| Immune thrombocytopenic purpura
Rhophylac vs Privigen
Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.Deep comparison between: Rhophylac vs Privigen with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrivigen has a higher rate of injection site reactions vs Rhophylac based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Privigen but not Rhophylac, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rhophylac
Privigen
At A Glance
IV or IM injection
Single dose
Rh(D) immune globulin
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Rh Isoimmunization
- Immune thrombocytopenic purpura
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Rh Isoimmunization 300 mcg (1500 IU) IV or IM injection; routine antepartum prophylaxis at week 28-30 of pregnancy; postpartum and obstetric complication doses within 72 hours of event; for excessive fetomaternal hemorrhage (>15 mL fetal RBCs), 300 mcg plus 20 mcg per mL fetal RBCs in excess of 15 mL; for incompatible transfusions, 20 mcg per 2 mL Rh(D)-positive whole blood within 72 hours of exposure.
Immune thrombocytopenic purpura 50 mcg per kg body weight by IV route only, administered at a rate of 2 mL per 15 to 60 seconds.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 200-800 mg/kg IV every 3-4 weeks.
Immune thrombocytopenic purpura 1 g/kg IV daily for 2 consecutive days (total dose 2 g/kg).
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Loading dose: 2 g/kg IV in divided doses over 2-5 consecutive days; maintenance dose: 1 g/kg IV every 3 weeks.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity to RHOPHYLAC or any of its components
- Newborn infant of a mother who received RHOPHYLAC postpartum
- History of anaphylactic or severe systemic reaction to human immune globulin
- Hyperprolinemia (product contains L-proline stabilizer)
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
Adverse Reactions
Most common - Rh Isoimmunization (>=0.5%) Nausea, dizziness, headache, injection-site pain, malaise
Most common - Immune thrombocytopenic purpura (>14%) Chills, pyrexia/increased body temperature, increased blood bilirubin, headache
Serious Intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, DIC (observed in ITP treatment)
Postmarketing Hypersensitivity reactions including anaphylactic shock, headache, dizziness, vertigo, hypotension, tachycardia, dyspnea, nausea, vomiting, rash, erythema, pruritus, chills, pyrexia, malaise, diarrhea, back pain
Most common (>5%) Headache, fatigue, nausea, chills, vomiting, back pain, elevated body temperature, diarrhea, cough, stomach discomfort, asthenia, hypertension, pain in extremity, hemolysis, anemia, leukopenia, rash
Serious Hypersensitivity, aseptic meningitis syndrome, hemolysis, renal dysfunction and acute renal failure, thrombosis, hyperproteinemia, hyponatremia, volume overload, transfusion-related acute lung injury
Postmarketing Decreased neutrophil count, hemoglobinuria, renal failure, photophobia, cerebral edema, pruritus, cardiac arrest, thromboembolism, Stevens-Johnson syndrome, ARDS, seizures, hepatic dysfunction
Pharmacology
Rh(D) immune globulin (anti-D) that suppresses immunization to Rh(D)-positive RBCs by accelerating their clearance; in ITP, forms Rh(D) immune globulin-RBC complexes preferentially removed by the reticuloendothelial system, causing Fc receptor blockade that spares antibody-coated platelets.
PRIVIGEN is an intravenous immunoglobulin that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; the mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rhophylac
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (10/12)
Privigen
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Rhophylac
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Privigen
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Rhophylac
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Privigen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Thrombocytopenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Privigen.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RhophylacView full Rhophylac profile
PrivigenView full Privigen profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.